In the same lines, we have demonstrated an inverse correlation between serum TGFβ levels with immunological T cell responses to a HER-2/neu hybrid peptide used to vaccinate prostate cancer patients [42]. The gene discussed is ERBB2; the disease is prostate carcinoma.